iScience (Sep 2022)

Exosomal MicroRNA signature acts as an efficient biomarker for non-invasive diagnosis of gallbladder carcinoma

  • Pinghua Yang,
  • Fengliang Song,
  • Xinwei Yang,
  • Xingzhou Yan,
  • Xinyu Huang,
  • Zhengjun Qiu,
  • Zhijian Wen,
  • Chi Liang,
  • Xianglei Xin,
  • Zhengqin Lei,
  • Kecheng Zhang,
  • Jue Yang,
  • Hu Liu,
  • Hongcheng Wang,
  • Shijun Xiang,
  • Liang Li,
  • Baohua Zhang,
  • Hongyang Wang

Journal volume & issue
Vol. 25, no. 9
p. 104816

Abstract

Read online

Summary: Through a three-step study that relies on biomarker discovery, training, and validation, we identified a set of five exosomal microRNAs (miRNAs) that can be used to evaluate the risk of gallbladder carcinoma (GBC), including miR-552-3p, miR-581, miR-4433a-3p, miR-496, and miR-203b-3p. When validated in 102 GBC patients and 112 chronic cholecystitis patients from multiple medical centers, the AUC of this combinatorial biomarker was 0.905, with a sensitivity of 81.37% and a specificity of 86.61%. The performance of this biomarker is superior to that of the standard biomarkers CA199 and CEA and is suited for GBC early diagnosis. The multi-clinicopathological features and prognosis of GBC patients were significantly associated with this biomarker. After building a miRNA-target gene regulation network, cell functions and signaling pathways regulated by these five miRNAs were examined. This biomarker signature can be used in the development of a noninvasive tool for GBC diagnosis, screening and prognosis prediction.

Keywords